uniQure (NASDAQ:QURE) CFO Christian Klemt Sells 6,217 Shares

uniQure N.V. (NASDAQ:QURE) CFO Christian Klemt sold 6,217 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $23.86, for a total transaction of $148,337.62. Following the sale, the chief financial officer directly owned 211,513 shares in the company, valued at $5,046,700.18. This trade represents a 2.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

uniQure Trading Down 8.6%

NASDAQ QURE opened at $15.63 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. uniQure N.V. has a one year low of $7.76 and a one year high of $71.50. The company has a 50-day simple moving average of $23.46 and a 200-day simple moving average of $29.59. The firm has a market capitalization of $973.59 million, a PE ratio of -3.56 and a beta of 0.66.

Institutional Investors Weigh In On uniQure

Several institutional investors have recently bought and sold shares of the stock. Avoro Capital Advisors LLC increased its stake in uniQure by 38.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after buying an additional 1,705,556 shares during the period. Aberdeen Group plc boosted its holdings in shares of uniQure by 25.1% in the fourth quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock valued at $88,030,000 after acquiring an additional 738,897 shares in the last quarter. State Street Corp boosted its holdings in shares of uniQure by 123.8% in the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after acquiring an additional 1,787,033 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of uniQure by 155.3% during the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after acquiring an additional 1,785,275 shares during the period. Finally, Jefferies Financial Group Inc. bought a new stake in uniQure during the second quarter worth approximately $29,217,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Analysts Set New Price Targets

QURE has been the topic of a number of research reports. Wells Fargo & Company dropped their price target on uniQure from $80.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 12th. Mizuho lowered their price objective on uniQure from $60.00 to $33.00 and set an “outperform” rating for the company in a research note on Monday, December 8th. Wall Street Zen cut uniQure from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. Chardan Capital restated a “buy” rating and set a $53.00 price target on shares of uniQure in a research report on Thursday, December 4th. Finally, HC Wainwright reiterated a “buy” rating and issued a $70.00 price objective on shares of uniQure in a research report on Tuesday, February 10th. Ten analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $58.33.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Unusual bullish options flow — heavy call buying (24,345 calls, ~181% above typical volume) suggests some traders are speculating on a near‑term rebound or event‑driven move.
• Negative Sentiment: Fresh FDA controversy: coverage highlights critical comments from FDA leadership about uniQure’s rejected rare‑disease therapy, which markets see as increasing regulatory risk for the program. uniQure: Shares Tumble On Fresh FDA Controversy – What Investors Should Know
• Negative Sentiment: FDA commissioner comments drew broad media coverage and were cited as the main driver of the selloff, amplifying short‑term downside as investors reassess approval odds. UniQure plummets as FDA’s Marty Makary disparages rejected rare disease drug
• Negative Sentiment: Multiple securities‑class action filings and firm notices: several law firms are publicizing suits or seeking lead plaintiffs for alleged misstatements during a specified class period — increasing legal and reputational risk and likely weighing on sentiment. Representative notices: DJS Law Group. uniQure N.V. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – QURE
• Negative Sentiment: Broad wave of law‑firm alerts and reminder notices (Rosen, Pomerantz, Faruqi, Robbins, Berger Montague, etc.) highlights that litigation momentum is building and that April 13, 2026 lead‑plaintiff deadlines are approaching — an added near‑term overhang. Example: Rosen Law Firm reminder. ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action – QURE
• Negative Sentiment: Market reaction summaries: analyst/news pieces attribute a large intraday drop to the FDA remarks and resulting uncertainty, reinforcing negative sentiment. Why Is uniQure Stock Down 30% Today?

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.